Form 4: SCPH Director Sells All Shares Post-MannKind Merger

Leonard D. Schaeffer, a director of scPharmaceuticals Inc., reported the disposition of all his common stock and stock options following the company's acquisition by MannKind Corporation.

Summary

• scPharmaceuticals Inc. (SCPH) completed its merger with MannKind Corporation, with Seacoast Merger Sub, Inc. (a MannKind subsidiary) acquiring SCPH.
• The merger became effective on October 7, 2025, following a tender offer.
• Tendering stockholders received $5.35 in cash per share, plus one non-tradable contingent value right (CVR) with potential payments up to $1.00 per CVR.
• Leonard D. Schaeffer, a director, disposed of 68,796 shares of common stock held directly and 43,104 shares held indirectly through Schaeffer Holdings LLC.
• All outstanding stock options with an exercise price less than $5.35 were cancelled and converted into a cash payment (difference between $5.35 and exercise price) and one CVR per share underlying the option.
• Mr. Schaeffer's disposed options included 30,000 at $3.85, 19,750 at $4.11, and 16,300 at $4.53.
• Following these transactions, Mr. Schaeffer beneficially owns 0 shares of common stock and 0 derivative securities of scPharmaceuticals Inc.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person and scPharmaceuticals shareholders who tendered, as the merger successfully closed, providing a cash payment and potential future value through CVRs. For the company itself, it marks a transition to private ownership under MannKind.

Positives

• Shareholders who tendered their shares received a cash payment of $5.35 per share, providing immediate liquidity and a premium.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential additional upside of up to $1.00 per CVR based on future regulatory and net sales milestones.
• The reporting person, Leonard D. Schaeffer, successfully monetized his equity and option holdings in scPharmaceuticals Inc. through the merger consideration.

Negatives

• scPharmaceuticals Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of MannKind Corporation.
• Existing shareholders no longer hold direct equity in scPharmaceuticals Inc. and will not participate in its future growth beyond the CVR terms.

Risks

• The contingent value rights (CVRs) are non-tradable and their value is dependent on the achievement of specific regulatory and net sales milestones by certain outside dates, meaning the full $1.00 per CVR is not guaranteed.

Future Outlook

scPharmaceuticals Inc. will continue its operations as a wholly-owned subsidiary of MannKind Corporation, integrating its business and products into MannKind's portfolio. The future performance and strategic direction will be determined by MannKind.

Industry Context

This transaction reflects a common trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, specialized firms to expand their product pipelines, market reach, or technological capabilities. The use of CVRs is also a frequent mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards.

Comparison to Industry Standards

• The acquisition structure, combining an upfront cash payment with contingent value rights (CVRs), is a standard approach in pharmaceutical and biotechnology mergers and acquisitions, particularly for companies with products in late-stage development or early commercialization.
• Comparable transactions often involve CVRs tied to regulatory approvals (e.g., FDA approval) or sales milestones, similar to the terms outlined for scPharmaceuticals Inc. shareholders.
• The premium offered in such deals typically reflects the target company's pipeline potential, market position, and synergies with the acquirer, aligning with typical industry benchmarks for strategic acquisitions.

Management Changes

Corporate Governance

Related Party Transactions

• Leonard D. Schaeffer's indirect beneficial ownership of 43,104 shares through Schaeffer Holdings LLC represents a related party transaction in the context of the merger disposition.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, monetizing their investment.
• Employees: scPharmaceuticals Inc. employees now work for a subsidiary of MannKind Corporation, potentially impacting organizational structure and benefits.
• Management: The independent board and executive management structure of scPharmaceuticals Inc. has been integrated into MannKind's corporate framework.

Next Steps

• scPharmaceuticals Inc. will operate as a wholly-owned subsidiary of MannKind Corporation.
• Shareholders holding CVRs will await the achievement of specified regulatory and net sales milestones for potential additional payments.

Key Dates

Keywords

scPharmaceuticals, MannKind, Merger, Acquisition, Tender Offer, SCPH, Contingent Value Right, CVR, Insider Transaction, Beneficial Ownership, Stock Options